Scheller joins from 23andMe

DiCE Molecules, a privately held company developing a next generation approach to small molecule drug discovery, today announced the appointment of Richard Scheller, chief scientific officer and head of therapeutics at 23andMe, to its board of directors. Dr. Scheller brings to DiCE nearly 20 years of leadership in drug discovery research and development.

Prior to 23andMe, Dr. Scheller spent 14 years at Genentech, where he served in various research and development roles until his retirement. Most recently, he was executive vice president of research and early development, focusing on the company's research strategy, drug discovery, business development and early drug development activities.